leon & Nucleus Medical Announce Collaboration to Develop & Manufacture Novel Transplantation Medicine
This license agreement enables Nucleus to utilize proprietary MicroJet Reactor (MJR) nanotechnology to improve stability, increase solubility and enhance bioavailability of its lead asset in immunotherapy.
It is estimated that over 80% of pipeline pharmaceutical APIs are poorly soluble in water. leon’s “enabling nano now” value proposition delivers novel, ready to use, validated, nano solutions that create value for partners and meets an unmet medical need for patients. Its technology provides formulation options that deliver a superior profile for API’s, reducing the drug payload while improving the onset of action and avoiding inter-intra patient variability.
Nucleus chose leon’s technology because of its scalability to every application, molecule and budget. From early compound screening to batch production, the platform ensures nanoparticle-based therapeutics are uniform, controlled and reproducible – driving speed to market and accelerating scale-up.
Andrea Cusack, CEO of leon, commented “We are very pleased and proud that Nucleus has selected us as its collaboration partner and will utilize our proprietary MJR technology for a feasibility assessment with its lead asset. We look forward to bringing valuable new medicines to patients worldwide.”
“Access to leon’s cutting-edge nanotechnology platform will create a new level of therapeutic efficiency and patient benefit for one of the most attractive APIs in transplantation medicine,” explained Wolfgang Beier, PhD, Managing Partner and CEO of Nucleus Medical GmbH. “We expect our product to become a new therapeutic entity on a global scale!”
leon delivers novel, validated and optimized solutions that create value for clients and provide better outcomes for their patients. It expedites APIs to deliver improved stability, increased solubility and enhanced bioavailability, revitalize forgotten formulations, and breathe new life into generics.
Nucleus Medical GmbH is a privately held pharmaceutical project development company, located in Munich, Germany, focused on the development of innovative application forms of leading APIs in solid organ transplant rejection medicine.
Total Page Views: 2013
